DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

MCK·McKesson Corporation

$.
-. (-.%)
High
$770.00
Open
$760.01
Market Cap
92.09B
52W High
$999.00
Low
$757.14
P. Close
$766.08
P/E
19.34
52W Low
$637.00
Fwd P/E
15.22
Mean Target
-
Technical Score (1D)
32
SELL
News Sentiment
61
BULLISH
McKesson stock has delivered a strong five-year performance, with a $1000 investment now valued at approximately $3,951. This represents an impressive annualized return of 31.83%, significantly outperforming the broader market by 19.67% annually. The substantial impact of compounded returns over this extended period is evident for shareholders. While this historical data highlights past success, it's important to monitor ongoing developments for future implications.
Earnings Summary
McKesson Corporation is a global leader in healthcare services, primarily focused on the distribution of pharmaceuticals and providing technology and business solutions to pharmacies and healthcare providers. Operating within the Healthcare sector and the Medical Distribution industry, McKesson plays a critical role in the healthcare ecosystem by ensuring access to medications and supporting various healthcare practices. Its business spans across the United States and internationally, encompassing segments like pharmaceutical distribution, technology solutions, and medical-surgical supplies. McKesson's recent quarterly performance has shown resilience and growth. In Q3 2025, the company reported actual EPS of $9.86, significantly beating the estimate of $9.05097, with revenue reaching $103.15 billion. This followed a Q2 2025 where actual EPS of $8.26 surpassed the estimate of $8.14657, and revenue was $97.827 billion. The Q1 2025 results showed actual EPS of $10.12, exceeding the estimate of $9.82674, with revenue at $90.823 billion. The most recent reported quarter, Q4 2026, saw actual EPS of $11.69, narrowly beating the estimate of $11.6764, with revenue of $96.295 billion against an estimate of $102.361 billion. This pattern indicates consistent EPS beats in the last four reported quarters, though revenue estimates have been missed in the most recent period. Historically, McKesson has demonstrated a strong year-over-year growth trajectory, particularly in its adjusted EPS. The company has a notable track record of beating analyst estimates for earnings per share, reinforcing its operational strength. While revenue performance has been robust, the most recent quarter's revenue miss against estimates warrants attention. The consistent pattern of EPS beats suggests effective cost management and strong underlying business performance, even amidst fluctuating revenue figures. Recent news indicates heightened investor attention and mixed analyst sentiment regarding McKesson. While some analysts have lowered price targets, others maintain positive ratings, citing strong long-range plans and fiscal year 2027 guidance. The company is advancing the separation of its Medical-Surgical Solutions business and has seen strategic partnerships within its Oncology & Multispecialty segment, such as the PRISM Vision Group's affiliations. McKesson reported robust fiscal 2026 adjusted EPS growth and significant shareholder returns, driven partly by specialty medication performance. Looking forward, investors will be watching McKesson's ability to execute its strategic initiatives, including the separation of its Medical-Surgical Solutions business. Key will be the company's performance against its fiscal year 2027 outlook, which has been described as "good enough" by some analysts. Monitoring the impact of its partnerships and the ongoing performance of its specialty medication segment will be crucial for assessing future growth and shareholder value.

EPS

EstBeatMiss
$7.44$8.64$9.84$11.04$12.24Q4'24Q1'25Q2'25Q3'25Q4'26Q1'27
QtrEstActual+/−
Q1'27$9.58 - -
Q4'26$11.68$11.69+0.1%
Q3'25$9.05$9.86+8.9%
Q2'25$8.15$8.26+1.4%
Q1'25$9.83$10.12+3.0%
Q4'24$7.99$8.03+0.5%

Revenue

EstBeatMiss
$88.7B$93.3B$97.9B$102.5B$107.2BQ4'24Q1'25Q2'25Q3'25Q4'26Q1'27
QtrEstActual+/−
Q1'27$105.0B - -
Q4'26$102.4B$96.3B-5.9%
Q3'25 - $103.2B -
Q2'25 - $97.8B -
Q1'25 - $90.8B -
Q4'24 - $95.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MCK Stock Snapshot

MCK is currently trading at $761.36, giving McKesson Corporation a market cap of 92.09B and a P/E ratio of 19.3. Today's range spans $757.14–$770.00, with shares opening at $760.01 and moving down $4.72 (0.6%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 61/100.

Over the past year MCK has traded between $637.00 and $999.00 - the current price is +19.5% off the 52-week low and -23.8% from the high.

MCK: large-cap, Healthcare, 92.09B market cap. (P/E: 19.3) Technical score 32/100 (SELL). Sentiment: bullish (61/100). Price: $761.36 (in the lower half of its 52-week range). Range: $637.00–$999.00. The SELL designation at this capitalization tier doesn't mean the stock is uninvestable - it means the risk/reward of buying dips hasn't been restored yet, and patience or an outright hedge is often the better posture until technical conditions improve.

When a large-cap Healthcare name with 92.09B in capitalization prints a SELL signal (32/100) alongside bullish news sentiment (61/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $761.36 (in the lower half of its 52-week range in the $637.00–$999.00 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…